# Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)

> **NCT05063786** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Spanish Breast Cancer Research Group** · enrollment: 27 (actual)

## Conditions studied

- Advanced Breast Cancer

## Interventions

- **BIOLOGICAL:** Trastuzumab
- **DRUG:** Alpelisib
- **DRUG:** Fulvestrant
- **DRUG:** Vinorelbine
- **DRUG:** Capecitabine
- **DRUG:** Eribulin

## Key facts

- **NCT ID:** NCT05063786
- **Lead sponsor:** Spanish Breast Cancer Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-09-14
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2025-09-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05063786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05063786, "Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05063786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*